Clinical trials: Schizophrenia Disorders
Schizophrenia, Schizoaffective Disorder
Brain Imaging, Cognitive Enhancement and Early Schizophrenia
The proposed project is designed to examine the effects of cognitive rehabilitation on brain structure and function in a randomized trial of 102 early course schizophrenia patients treated for 18 months with either cognitive…
- Trial name
- BICEPS (NCT01561859)
- Testing
- Cognitive Enhancement Therapy, Enriched Supportive Therapy
- Where
- 5 sites in United States
- Volunteers
- 102 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia
The Effects of Nicotine on Cognition in Schizophrenia
Patients with schizophrenia have a variety cognitive deficits and nicotine has been shown to normalize some of these deficits. The purpose of this study is to investigate the effects of nicotine on cognition in schizophrenia.We…
- Trial name
- NCT00383747
- Testing
- transdermal nicotine patch
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Psychosis
A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
This is a safety study evaluating the subjects who participated in previous Organon trials of the drug Org 24448. Patients will undergo a Screening visit, 1 or 2 Evaluation visits, and a possible Follow-Up period.
- Trial name
- NCT00780585
- Testing
- SCH 900460
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of 3 different doses of paliperidone extended release (ER) compared to placebo in patients diagnosed with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00299715
- Testing
- Paliperidone extended-release
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Physical Activity, Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)
Expanded Game Squad for Neurodiverse Youth
The proposed study will pilot the use of an adapted Game Squad intervention aimed at improving physical activity and other important health behaviors (nutrition, sleep hygiene, screen time habits) for children and adolescents…
- Conditions
- Physical Activity, Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Health Behavior, Developmental Disorder
- Trial name
- NDGameSquad (NCT03665415)
- Testing
- NDGameSquad
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Merrimack College
Schizophrenia
D-serine and Cognitive Remediation in Schizophrenia
The investigators will test the effects of 3 days of D-serine (DSR) on auditory plasticity in a sensory based remediation (SBR) paradigm
- Trial name
- NCT02156908
- Testing
- D-serine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Weight Gain, Sialorrhea
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or…
- Trial name
- FOCUS (NCT00683891)
- Testing
- FazaClo (clozapine, USP) ODT
- Where
- 2 sites in United States
- Sponsor
- Azur Pharma, Inc
Schizophrenia
Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms
Memantine as an add-on therapy to clozapine may improve schizophrenia negative symptoms and cognitive functioning.
- Trial name
- NCT00757978
- Testing
- memantine
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Schizophrenia
Culturally Based Family Therapy for Improving Treatment Outcome for People With Schizophrenia
This study will evaluate the effectiveness of a culturally based family therapy intervention in improving treatment outcome in people with schizophrenia.
- Trial name
- NCT00356317
- Testing
- Culturally informed therapy for schizophrenia (CIT-S), Psychoeducation treatment as usual
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Miami
Schizophrenia
Cinematic Virtual Reality Intervention for Improving Psychosocial Functioning in Individuals With Schizophrenia
Virtual reality (VR) is a novel and innovative intervention method increasingly used in psychiatric research and treatment. VR allows individuals to experience realistic, everyday social situations in a safe and controlled…
- Trial name
- NCT07326618
- Testing
- Cinematic Virtual Reality Psychososcial Treatment Program Group
- Where
- Turkey (Türkiye)
- Volunteers
- 37 people
- Sponsor
- Dokuz Eylul University
Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders
Ascertaining Diagnosis Classification With Elicited Speech
Cross-sectional observational study of the relationship between speech patterns and psychiatric symptoms and disorders.
- Conditions
- Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders, Depressive Disorder, Anxiety Disorders
- Trial name
- ACES (NCT05601063)
- Testing
- Winterlight Speech Assessment
- Where
- United States
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Schizophrenia
Promoting Activity and Cognitive Enrichment in Schizophrenia (PACES)
This project will conduct a confirmatory efficacy trial of two novel psychosocial interventions, Cognitive Enhancement Therapy and Enriched Supportive Therapy, for the treatment of persistent negative symptoms in schizophrenia.
- Trial name
- NCT04143126
- Testing
- Cognitive Enhancement Therapy, Enriched Supportive Therapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Pittsburgh
Acute Agitation
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a…
- Trial name
- SNAP101 (NCT03624322)
- Testing
- Zyprexa IM, Zydis, INP105
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
- Trial name
- NCT03669640
- Testing
- RO6889450
- Where
- 45 sites in United States, Japan and 2 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
A Single Ascending Dose (SAD; Part A) and Multiple Ascending Dose (MAD; Part B) Phase 1 Study of LB-102 N-Methyl amisulpride) in healthy volunteers.
- Trial name
- NCT04187560
- Testing
- LB-102
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- LB Pharmaceuticals Inc.
Schizophrenia
Effects of Cognitive Remediation Therapy on Schizophrenia Patients Through Functional Magnetic Resonance Imaging
Cognitive Remediation Therapy (CRT) can enhance cognitive performance in patients with schizophrenia improving clinical outcome. However, the neurobiological mechanism underlying cognitive improvement is not well understood.
- Trial name
- NCT01318850
- Testing
- Cognitive Remediation Therapy, Psychoeducation, Healthy controls
- Where
- Spain
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Schizophrenia and Related Disorders
Mechanistic Clinical Trial of Individualized tDCS for Hallucinations in Schizophrenia
This project compares standard tDCS to individualized high-definition tDCS (HD-tDCS) for treatment of auditory verbal hallucinations in schizophrenia.
- Trial name
- NCT04248010
- Testing
- neuroConn DC-Stimulator MR, Soterix MxN HD-tES
- Sponsor
- Columbia University
Schizophrenia and Disorders With Psychotic Features, Disorders
Investigator Initiated Study - Asenapine Early Psychosis
We propose a use of a unique facility, the databank at the CNDV, to examine the impact of switching subjects to asenapine in an open-label naturalistic setting.
- Trial name
- NCT01968161
- Testing
- Asenapine
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
Alcohol Dependence, Bipolar Disorder
Treatment of Alcohol Dependence and Comorbid Bipolar Disorder
The study will determine if individuals with co-occurring bipolar disorder and alcohol dependence report reduced alcohol consumption, improvement in mood symptoms, and cognitive performance if treated with lamotrigine plus their…
- Conditions
- Alcohol Dependence, Bipolar Disorder, Depression, Mania
- Trial name
- NCT01015586
- Testing
- Lamotrigine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Medical University of South Carolina
Depression - Major Depressive Disorder, Schizophrenia Disorders
Development and Application of Precision Treatment Strategies for Common Mental Disorders
Schizophrenia (SCH), major depressive disorder (MDD), and bipolar disorder (BPD) are prevalent, disabling psychiatric conditions that not only cause significant suffering for affected individuals and their families but also…
- Conditions
- Depression - Major Depressive Disorder, Schizophrenia Disorders, Bipolar Disorder (BD)
- Trial name
- NCT06729541
- Testing
- Multigenetic Pharmacogenomics-Guided Treatment (MPGT)
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University